Plain-English translation of NCT05456503 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study tests whether a specialized brain imaging scan called PET can detect abnormal tau protein buildup in people with different types of memory loss and thinking disorders. Researchers want to see if this imaging method can help doctors better understand and diagnose conditions like Alzheimer's disease and frontotemporal dementia. The scan is designed to visualize harmful protein accumulation in the brain that causes these conditions.
Current methods for diagnosing memory and thinking disorders are limited, and doctors need better tools to see what's happening inside the brain during these diseases. This new imaging method could help doctors spot problems earlier and more accurately, leading to better diagnosis and potentially better treatment options in the future.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive one specialized brain imaging scan using the tracer—a harmless radioactive dye that helps doctors see protein buildup in your brain. The scan itself typically takes about an hour. You will also continue participating in your regular UNICORN study visits, which include yearly MRI scans, memory and thinking tests, and occasional blood tests or spinal fluid collection to measure biomarkers related to brain disease.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States